-5%
(Levodopa + Carbidopa + Entacapone)
Tridopa is indicated for the treatment of adult patients with Parkinson’s disease who experience end-of-dose motor fluctuations and are not stabilized on levodopa/dopa decarboxylase (DDC) inhibitor therapy.
- Children: Safety and efficacy not established.
- Elderly: No specific dose adjustment needed.
- Hepatic impairment: Use with caution in mild–moderate cases.
- Renal impairment: Use cautiously in severe impairment, including dialysis patients.
Levodopa: Dopamine precursor; crosses the blood-brain barrier and converts into dopamine to relieve motor symptoms of Parkinson’s disease.
Carbidopa: Dopa decarboxylase (DDC) inhibitor; prevents peripheral metabolism of levodopa, increasing its availability in the brain.
Entacapone: Selective catechol-O-methyltransferase (COMT) inhibitor; prolongs plasma levodopa levels and enhances clinical response.
Together, the combination provides a greater and sustained dopaminergic effect, improving control of Parkinson’s symptoms.
If therapy is stopped, switch back to levodopa/DDC inhibitor and adjust doses of other antiparkinsonian drugs as needed.